Search results
Author(s):
Paul Guedeney
,
Birgit Vogel
,
Roxana Mehran
Added:
3 years ago
Dual antiplatelet therapy (DAPT) including aspirin and a P2Y12 inhibitor is the current gold standard for the treatment and mid-term secondary prevention of acute coronary syndrome (ACS).1–4 However, despite the use of potent P2Y12 inhibitors such as ticagrelor or prasugrel, patients remain at high ischaemic risk after ACS. More specifically, in the prasugrel treatment arm of the TRial to Assess…
View more
Author(s):
Dipti Itchhaporia
Added:
4 months ago
AHA 23 - Dr Dipti Itchhaporia (Hoag Heart and Vascular Institute, US), interventional cardiologist and Past President of the American College of Cardiology (ACC) highlights the top three late-breaking science trials from the 2023 AHA Scientific Sessions with the potential to change medical practices.Trials discussed in detail include:SELECT: Semaglutide and Cardiovascular Outcomes in Obesity…
View more
Author(s):
Yugo Yamashita
Added:
7 months ago
What's hot at the European Society of Cardiology (ESC) Congress 2023?
Browse our curated coverage of the latest updates in cardiology from Amsterdam.
Watch ourView From the Thoraxcenterseries for a concise line up of the most awaited trials fromProf Nicolas Van MieghemandDr Joost Daemen.
For a deeper dive into key clinical trial data and its applicability, host,Dr Harriette Van…
View more
Author(s):
Andrew Archbold
Added:
3 years ago
Patients who undergo coronary artery stenting require dual antiplatelet therapy (DAPT) in order to reduce their risk of stent thrombosis. Long-term oral anticoagulation (OAC) is indicated for the primary and secondary prevention of thrombotic events in patients with atrial fibrillation (AF), mechanical heart valves, intra-cardiac thrombus, venous thromboembolic disease and some hypercoagulable…
View more
Author(s):
Antonio Greco
,
Claudio Laudani
,
Carla Rochira
,
et al
Added:
1 year ago
Author(s):
Michael Tsang
,
Sanjit Jolly
Added:
3 years ago
Many advances have been made in the management of ST elevation myocardial infarction (STEMI) over the past three decades.1 This is owed to insight into role that thrombus has in the obstruction of the infarct-related artery (IRA) and the subsequent cascade of the myocardial ischaemia, cell oedema and myocardial necrosis. The institution of reperfusion therapy has revolutionised the care of…
View more
Author(s):
Azfar Zaman
,
Bernard Prendergast
,
David Hildick-Smith
,
et al
Added:
11 months ago
Author(s):
Luca Testa
,
Azeem Latib
Added:
3 years ago
Leaflet motion abnormalities (LMAs) are a relatively new entity in the field of transcatheter aortic valves (TAVs).1–4 They can be associated with the thrombosis of the bioprosthesis (TAVT), often leading to dramatic clinical scenarios1 or, on the other hand, they can result in a hypoattenuated leaflet thickening (HALT) and/or reduced leaflet motion (RELM), both usually associated with gradients…
View more
Author(s):
Sri Raveen Kandan
,
Thomas W Johnson
Added:
3 years ago
Antiplatelet Therapy
Current guidelines support the early administration of oral antiplatelet agents upstream of angiographic assessment and intervention.1 Aspirin is commonly given by the first medical contact and additional oral antiplatelet drugs are administered on arrival in hospital (see Figure 1).
Aspirin
The efficacy of aspirin in acute ST-segment elevation myocardial infarction (STEMI)…
View more
Author(s):
Stuart J Head
,
Ad JJC Bogers
,
A Pieter Kappetein
Added:
3 years ago
Valvular Heart Surgery
The field of cardiac surgery is urgently in need of new anticoagulant agents. Approximately 300,000 prosthetic valves are implanted yearly, after which lifelong anticoagulation therapy is mandatory as thromboprophylaxis. To date, vitamin K antagonists (VKAs), such as warfarin, remain the only licensed agents to prevent mechanical valve-induced thromboembolic events but…
View more